Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Stock Short Interest Drops 97.4%

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) was the target of a large drop in short interest in the month of September. As of September 30th, there was short interest totaling 33,851 shares, a drop of 97.4% from the September 15th total of 1,297,436 shares. Based on an average trading volume of 130,379 shares, the short-interest ratio is presently 0.3 days. Approximately 0.0% of the company’s shares are short sold.

Shionogi & Co., Ltd. Unsponsored ADR Stock Down 0.6%

Shares of SGIOY traded down $0.05 during trading on Friday, reaching $8.70. The company’s stock had a trading volume of 131,152 shares, compared to its average volume of 188,565. The company has a market cap of $14.81 billion, a price-to-earnings ratio of 8.70, a P/E/G ratio of 3.14 and a beta of 0.08. The company has a quick ratio of 1.00, a current ratio of 1.14 and a debt-to-equity ratio of 0.01. The company has a fifty day moving average of $9.07 and a two-hundred day moving average of $9.33. Shionogi & Co., Ltd. Unsponsored ADR has a twelve month low of $7.65 and a twelve month high of $12.00.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last issued its quarterly earnings results on Monday, August 3rd. The company reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.18 by $0.18. The business had revenue of $1.04 billion during the quarter, compared to analyst estimates of $970.69 million. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 46.67% and a return on equity of 16.13%. On average, sell-side analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.82 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SGIOY has been the subject of a number of recent research reports. Jefferies Financial Group upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 14th. The Goldman Sachs Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research note on Monday, June 15th. Two research analysts have rated the stock with a Strong Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy”.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Osaka. Founded in 1878, the company discovers, develops, manufactures and markets prescription medicines, with a focus on infectious diseases, central nervous system disorders and other areas of unmet medical need.

Shionogi’s portfolio includes Xofluza (baloxavir marboxil), an antiviral treatment for influenza, and F. (fostemsavir), an HIV treatment marketed in certain regions. The company also develops medicines for conditions including pain, psychiatric disorders and other diseases, while pursuing research in areas such as antimicrobial resistance and novel anti-infective therapies.

Shionogi primarily serves the Japanese market and has expanded its international presence through subsidiaries, licensing arrangements and commercial partnerships in North America, Europe and other regions.